Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548AM2)(COMPLETED)

This study has been completed.

Study NCT00302081 Information provided by Schering-Plough

First Received: March 10, 2006 Last Updated: June 24, 2009 History of Changes

Study Type:	Interventional
Study Design:	Randomized, Open Label, Dose Comparison, Parallel Assignment
Condition:	Hepatitis C, Chronic
Interventions:	Biological: peginterferon alfa-2b (SCH 54031) Drug: ribavirin (SCH 18908)

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
PEG2b 1.5/R (24 Weeks)	PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
PEG2b 1.0/R (24 Weeks)	PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
PEG2b 1.5/R (16 Weeks)	PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks

Baseline Measures

	PEG2b 1.5/R (24 Weeks)	PEG2b 1.0/R (24 Weeks)	PEG2b 1.5/R (16 Weeks)	Total
Number of Participants [units: participants]	230	224	228	682
Age [units: years] Mean ± Standard Deviation	38.8 ± 10.2	39.9 ± 11.2	39.7 ± 11.1	39.5 ± 10.9
Gender [units: participants]
Female	91	78	80	249
Male	139	146	148	433

Outcome Measures

1. Primary:

The Number of Participants Who Achieve a Sustained Virologic Response (SVR) [ 24-week treatment duration for Arms [Peg2b 1.5/R(24 weeks)] and [PEG2b 1.0/R(24 weeks]); 16-week treatment duration for Arm [PEG2b 1.5/R(16 weeks]. Follow-up of 24 weeks for each arm. ]

Show Outcome Measure 1

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Head, Clinical Trials Registry & Results Disclosure Group
Organization: Schering-Plough
e-mail: ClinicalTrialsDisclosure@spcorp.com

No publications provided

Responsible Party:	Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group )
Study ID Numbers:	P03548
Study First Received:	March 10, 2006
Results First Received:	April 29, 2009
Last Updated:	June 24, 2009
ClinicalTrials.gov Identifier:	NCT00302081 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices; Israel: Ministry of Health; India: Drugs Controller General of India; Poland: Ministry of Health; Indonesia: National Agency for Drug and Food Control; Singapore: Health Sciences Authority; Malaysia: Ministry of Health; Thailand: Thai Drug Control Division, Food and Drug Administration, Ministry of Public Health